

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 18<sup>th</sup> December, 2017

### ORDER

S. O. In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

**Table**

Sl. No	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
1.	Ferrous Ascorbate + Folic Acid + Cyanocobalamin + Zinc Sulphate Monohydrate tablet (Autrin - XT)	Each film coated tablet contains: Ferrous Ascorbate eq. to Elemental Iron 100mg, Folic Acid IP 1.5mg, Cyanocobalamin IP 15 mcg, Zinc Sulphate Monohydrate IP eq. to Elemental Zinc 22.5mg	1 Tablet	M/s Tirupati Medicare Limited / M/s Pfizer Limited	3.63
2.	Rosuvastatin + Clopidogrel Capsule (Roseday CV 10)	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin (As granules) 10mg, Clopidogrel Bisulphate IP eq. to Clopidogrel (As a film coated tablet) 75mg	1 Capsule	M/s Aeon Formulation Pvt. Ltd. / M/s USV Private Limited	13.37
3.	Teneligliptin + Metformin tablet (Ten20 M 1000)	Each uncoated bilayered tablets contains: Teneligliptin Hydrobromide hydrate eq. to Teneligliptin 20mg, Metformin HCL 1000mg (as extended release)	1 Tablet	M/s Glenamark Pharmaceuticals Ltd. / M/s Centaur Pharmaceuticals Pvt. Ltd.	10.87
4.	Clobetasol + Clotrimazole + Neomycin Sulphate Cream	Each gm contains: Clobetasol Propionate IP 0.05%w/w, Clotrimazole IP 1.00% w/w, Neomycin Sulphate IP 0.50%w/w	1 GM	M/s Mankind Pharma Ltd./ M/s Pharma Force Lab.	2.92
5.	Moxifloxacin +	Each Coated Sustained Release	1 Tablet	M/s Akums Drugs	33.05

	Cefixime Tablets (Moximac Plus)	tablet contains: Moxifloxacin Hydrochloride BP eq. to Moxifloxacin 400mg, Cefixime IP (as trihydrate) eq. to Anhydrous Cefixime 400mg		and Pharmaceuticals Ltd. / M/s Macleods Pharmaceuticals Ltd.	
6.	Moxifloxacin + Cefixime Tablets (Macflo Plus)	Each Coated Sustained Release tablet contains: Moxifloxacin Hydrochloride BP eq. to Moxifloxacin 400mg, Cefixime IP (as trihydrate) eq. to Anhydrous Cefixime 400mg	1 Tablet	M/s Akums Drugs and Pharmaceuticals Ltd. / M/s Macleods Pharmaceuticals Ltd.	33.05
7.	Tramadol + Paracetamol Tablet	Each Film Coated tablet contains: Tramadol Hydrochloride IP 37.5mg, Paracetamol IP 325mg	1 Tablet	M/s Anglo French Drugs & Industries Ltd.	5.57
8.	Rosuvastatin + Aspirin + Clopidogrel Tablet	Each film coated bilayered tablet contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg, Aspirin IP 75mg, Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg	1 Tablet	M/s Safetab Life Science / M/s Intas Pharmaceuticals Limited	9.97
9.	Teneligliptin + Metformin Tablet	Each uncoated bilayered tablets contains: Teneligliptin Hydrobromide hydrate eq. to Teneligliptin 20mg, Metformin HCL 500mg (as extended release)	1 Tablet	M/s Synokam Pharma limited/ M/s Cadila Pharmceuticals Ltd.	9.62
10.	Teneligliptin + Metformin Tablet	Each uncoated bilayered tablets contains: Teneligliptin Hydrobromide hydrate eq. to Teneligliptin 20mg, Metformin HCL 1000mg (as extended release)	1 Tablet	M/s Synokam Pharma limited/ M/s Cadila Pharmceuticals Ltd.	10.87
11.	Paracetamol + Caffeine + Phenylephrine + Diphenhydramine Tablet	Each uncoated tablet contains: Paracetamol IP 500mg, Caffeine (Anhydrous) IP 30mg, Phenylephrine Hydrochloride IP 5mg, Diphenhydramine Hydrochloride IP 25mg	1 Tablet	M/s Biochem Pharmaceutical Industries Ltd.	2.57
12.	Ramipril + Amlodipine Tablet	Each uncoated tablet contains: Ramipril IP 5mg, Amlodipine Besilate IP eq. to Amlodipine 5mg	1 Tablet	M/s Lupin Limited	4.11
13.	Teneliglitptin + Metformin Tablet	Each Film uncoated bilayer tablet contains: Teneliglitptin Hydrobromide Hydrate 20mg eq. to Tenegliptin 20mg, Metformin Hydrochloride IP 1000mg (In Sustained Release form)	1 tablet	M/s Lupin Limited / M/s Unichem Laboratories Ltd.	10.87
14.	Teneliglitptin +	Each uncoated bilayer tablet	1 Tablet	M/s Lupin Limited /	9.62

	Metformin Tablet	contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg, Metformin Hydrochloride IP 500mg		M/s Unichem Laboratories Ltd	
15.	Rosuvastatin + Clopidogrel Capsule (Roistar CV 10/75)	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (As Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as Pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd. / M/s Unichem Laboratories Ltd.	13.37
16.	Rosuvastatin + Clopidogrel Capsule (Roistar CV 20/75)	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as Pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd. / M/s Unichem Laboratories Ltd.	7.80
17.	Diclofenac Injection	Each ml contains: Diclofenac Sodium IP 75mg Injection	1 ML	M/s Cadila Healthcare Ltd.	13.71
18.	Teneligliptin + Metformin Tablet (EFIGLIN M)	Each uncoated Bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg, Metformin HCl 500mg	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s MedoPharm,	9.62
19.	Rosuvastatin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As granules), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as to film coated tablets)	1 Capsule	M/s GKM New Pharma / M/s Cadila Healthcare Ltd.	7.80
20.	Rosuvastatin + Clopidogrel Capsule (Roseday CV 20)	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin (As Pellets) 20mg, Clopidogrel Bisulphate IP eq. to Clopidogrel (As Pellets ) 75mg	1 Capsule	M/s Synokem Pharmaceuticals Ltd. / M/s USV Pvt. Ltd,	7.80
21.	Teneligliptin + Metformin Tablet	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg, Metformin HCL 500mg (as sustained release)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Ltd.	9.62
22.	Teneligliptin + Metformin Tablet	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg, Metformin HCL 1000mg (as sustained release)	1 Tablet	/s Synokem Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Ltd.	10.87
23.	Metformin + Glimepiride + Voglibose Tablet	Each tablet contains: Metformin HCL 500mg (as sustained release form), Glimepiride 2mg,	1 Tablet	M/s Sunglow Pharmaceuticals Pvt. Ltd. / M/s Intas Pharmaceuticals	9.39

		Voglibose 0.3mg		Ltd.	
24.	Paracetamol Tablet	Each tablet contains: Paracetamol IP (as Immediate Release) 300mg, Paracetamol IP (as Sustained Release) 700mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Strassenburg Pharmaceuticals Ltd.	3.15
25.	Aceclofenac + Paracetamol Tablet	Each Tablet contains: Aceclofenac IP 100mg, Paracetamol IP 325mg	1 Tablet	M/s Rivpra Formulation Pvt. Ltd. / M/s Cadila Pharmaceuticals Ltd.	2.78
26.	Rosuvastatin + Clopidogrel Capsule	Each Hard gelatin capsule contains: Rosuvastatin 10mg, Clopidogrel 75mg	1 Capsule	M/s Synokem Pharmaceuticals Ltd. / M/s Cadila Pharmaceuticals Ltd.	13.37
27.	Teneligliptin + Metformin Tablet (EFIGLIN M 1000)	Each uncoated Bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg, Metformin Hydrochloride IP 1000mg (as Sustained Release form)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s MedoPharm	10.87
28.	Olmesartan + Amlodipine Tablet	Each film coated tablet contains: Olmesartan Medoxomil IP 20mg, Amlodipine Besylate IP eq. to Amlodipine 5mg,	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Zuventus Healthcare Limited	7.24
29.	Telmisartan + Metoprolol Tablet (Xstan-Beta 25mg)	Each film coated tablet contains: Telmisartan IP 40mg, Metoprolol Tartrate IP 25mg (ER)	1 Tablet	M/s Akums Drugs and Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd.	7.62
30.	Telmisartan + Metoprolol Tablet (Xstan-Beta 50mg)	Each film coated tablet contains: Telmisartan IP 40mg, Metoprolol Tartrate IP 50mg (ER)	1 Tablet	M/s Akums Drugs and Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd.	9.16
31.	Voglibose + Glimepride + Metformin Tablet	Each uncoated bilayered tablet contains: Voglibose IP 0.2mg, Glimepride IP 1mg, Metformin HCL IP 500mg (SR)	10 Tablets	M/s Windlas Biotech Pvt. Ltd. / M/s Zuventus Healthcare Limited	68.50
32.	Atorvastatin + Clopidogrel Capsules (Atchol CV 10mg)	Each hard gelatin capsule contains: Atorvastatin Calcium eq. to Atorvastatin (as pellets) 10mg, Clopidogrel (as pellets) 75mg.	10 Capsule	M/s Synokem Pharmaceuticals Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd.	83.94
33.	Voglibose + Glimepride +	Each uncoated bilayered tablet contains:	1 Tablet	M/s Windlas Biotech Pvt. Ltd.	8.68

	Metformin Tablet	Voglibose IP 0.2mg, Glimepride IP 2mg, Metformin Hydrochloride IP 500mg (SR)		/M/s Zuventus Healthcare Limited	
34.	Teneligliptin + Metformin Tablet (Tenephron M)	Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg, Metformin Hydrochloride 500mg (SR)	1 Tablet	M/s Windlas Biotech Limited / M/s Abbott India Limited	9.62
35.	Teneligliptin + Metformin Tablet (Tenephron M Forte)	Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg, Metformin HCl 1000mg (SR)	1 Tablet	M/s Windlas Biotech Limited / M/s Abbott India Limited	10.87
36.	Teneligliptin + Metformin Tablet (TYTIN M)	Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide hydrate eq. to Teneligliptin 20mg, Metformin Hydrochloride 500mg (as extended release)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Wockhardt Ltd.	9.62
37.	Tacrolimus Capsule	Each Hard gelatin capsule contains: Tacrolimus IP 0.25mg	1 Capsule	M/s Emcure Pharmaceuticals Ltd,	10.82
38.	Telmisartan + Amlodipine Tablet	Each uncoated bilayer tablet Contains: Telmisartan IP 80mg, Amlodipine Besilate IP 5mg	10 Tablet	M/s J. K. Print Packs / M/s Mankind Pharma Ltd.	106.05
39.	Telmisartan + Amlodipine Tablet (Tigatel AM 40)	Each film coated tablet contains: Telmisartan IP 40mg, Amlodipine Besylate IP eq. to Amlodipine 5mg	1 Tablet	M/s Sun Pharma Laboratories Limited	6.90
40.	Cefixime + Ofloxacin Tablet (Ranixime Plus)	Each film coated tablet contains: Cefixime Trihydrate eq. to Cefixime Anhydrous IP 200mg, Ofloxacin IP 200mg	1 Tablet	M/s Theon Pharmaceuticals Limited / M/s Sun Pharmaceutical Industrial Limited	9.46
41.	Teneligliptin + Metformin Tablet (Glypte M)	Each film coated tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg, Metformin Hydrochloride 500mg	1 Tablet	M/s Precise Chemipharma Pvt. Ltd. / M/s Franco India Pharmaceuticals Private Limited	9.62
42.	Teneligliptin + Metformin Tablet (Glypte M Forte)	Each film coated tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg, Metformin Hydrochloride 1000mg	1 Tablet	M/s Precise Chemipharma Pvt. Ltd. / M/s Franco India Pharmaceuticals Private Limited	10.87
43.	Glemipiride + Metformin Tablet (Ziglim - M1 Forte)	Each uncoated bilayered tablet contains: Glemipiride IP 1mg, Metformin Hydrochlorde IP 1000mg (as SR form)	1 Tablet	M/s Inventia Healthcare Pvt. Ltd. / M/s FDC Limited	5.69

44.	Glempiride + Metformin Tablet (Ziglim - M2 Forte)	Each uncoated bilayered tablet contains: Glimepiride IP 2mg, Metformin Hydrochloride IP 1000mg (as SR form)	1 tablet	M/s Inventia Healthcare Pvt. Ltd. / M/s FDC Limited	7.19
45.	Diclofenac Injection	Each ml contains: Diclofenac Sodium IP 75mg/ml	1 ml	M/s Zydus Healthcare Ltd.	13.71
46.	Doxorubicin (Pegylated Liposomal) Injection	Each ml contains: Doxorubicin HCL 2mg (Pegylated Liposomal) water for Injection	1 ml	M/s Natco Pharma Ltd.	694.29
47.	Telmisartan + Indapamide Tablet	Each uncoated bilayered tablet contains: Telmisartan IP 40mg Indapamide IP 1.5mg	1 Tablet	M/s Windlas Biotech Pvt. Ltd. / M/s Mankind Pharma Ltd.	8.48
48.	Paracetamol + Mefenamic Acid Injection (Zydol-P DS)	Each 5ml contains: Paracetamol 250mg Mefenamic Acid 100mg	1 ml	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Jenburkt Pharmaceuticals Ltd.	0.57
49.	Paracetamol + Phenylephrine + Chlorpheniramine + Sodium Citrate + Menthol Injection	Each 5ml contains: Paracetamol 125mg Phenylephrine Hydr,ochloride IP 5mg, Chlorpheniramine Maleate IP 0.5mg, Sodium Citrate IP 60mg, Menthol IP 1mg	1 ml	M/s Relax Pharmaceuticals Ltd. / M/s Magnet Labs Pvt. Ltd.	0.57
50.	Atorvastatin + Clopidogrel Capsule (Atocor CV)	Each hard gelatin capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 10mg (As film coated tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As 2 film coated 37.5mg each tablet)	10 Capsule	M/s Windlas Biotech Pvt. Ltd. / M/s Dr. Reddy's Laboratories Ltd.	83.94
51.	Tacrolimus Capsule	Each hard gelatin capsule contains: Tacrolimus premix (20%) eq. to Tacrolimus IP 0.25mg	1 Capsule	M/s Intas Pharmaceuticals Ltd.	10.82
52.	Atorvastatin + Clopidogrel Capsule (Avas 10 Gold)	Each capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 10mg (As film coated tablet) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As 2 film coated 37.5mg each tablet)	10 Capsule	M/s Micro Lab. Ltd.	83.94
53.	Atorvastatin + Clopidogrel Capsule (Astin 10 Gold)	Each capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 10mg (As film coated tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As 2 film coated 37.5mg each tablet)	10 Capsule	M/s Micro Lab. Ltd.	83.94

54.	Glimepiride + Metformin Tablet (DIAPRIDE M 0.5)	Each uncoated bilayered tablet contains: Glimepiride IP 0.5mg, Metformin Hydrochloride IP 500mg (SR)	1 Tablet	M/s Micro Lab. Ltd.	2.22
55.	Telmisartan + Hydrochlorothiazide Tablet (Tigatel H 40)	Each uncoated tablet contains: Telmisartan IP 40mg, Hydrochlorothiazide IP 12.5mg	1 Tablet	M/Sun Pharma Laboratories Ltd.	7.16
56.	Telmisartan + Hydrochlorothiazide Tablet (Tigatel H 80)	Each uncoated tablet contains: Telmisartan IP 80mg, Hydrochlorothiazide IP 12.5mg	1 Tablet	M/Sun Pharma Laboratories Ltd.	11.12
57.	Telmisartan + Amlodipine Tablet (Tigatel AMH 40)	Each uncoated tablet contains: Telmisartan IP 40mg, Amlodipine Besylate IP Eq. to Amlodipine 5mg, Hydrochlorothiazide IP 12.5mg	1 Tablet	M/s Sun Pharma Laboratories Ltd.	7.48
58.	Telmisartan + Amlodipine Tablet (Tigatel AMH 80)	Each uncoated tablet contains: Telmisartan IP 80mg, Amlodipine Besylate IP Eq. to Amlodipine 5mg, Hydrochlorothiazide IP 12.5mg	10 Tablet	M/s Sun Pharma Laboratories Ltd.	117.83
59.	Sofosbuvir + Velpatasvir Tablet	Each film coated tablet contains: Sofosbuvir 400mg, Velpatasvir 100mg	28 tablets	M/s Hetro Lab Limited / M/s Emcure Pharmaceutical Limited	15625.00
60.	Methylprednisolone Injection	Each Vial contains: Methylprednisolone Sodium Succinate USP. Eq. to Methylprednisolone 125mg	1 Vial	M/s Aqua Vitoe Laboratories / M/s Claris Injectable Limited,	228.44
61.	Methylprednisolone Injection	Each Vial contains: Methylprednisolone Sodium Succinate USP. Eq. to Methylprednisolone 500mg	1 Vial	M/s Aqua Vitoe Laboratories / M/s Claris Injectable Limited,	469.76
62.	Methylprednisolone Injection	Each Vial contains: Methylprednisolone Sodium Succinate USP. Eq. to Methylprednisolone 1000mg	1 Vial	M/s Aqua Vitoe Laboratories / M/s Claris Injectable Limited,	782.78
63.	Bortezomib Injection (BortiRel)	Each vial contains: Bortezomib IP 3.5mg Injection	1 Vial	M/s Reliance Life Sciences Pvt. Ltd.	12500.00

Note:

- (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.

- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) The concerned manufacturer of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturer, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

PN/183/51/2017/F

F. No. 8(51)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India  
Ministry of Chemicals and Fertilizers  
Department of Pharmaceuticals  
National Pharmaceutical Pricing Authority

New Delhi, the 18<sup>th</sup> December, 2017

**ORDER**

**S.O. \_\_\_\_\_** In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S.O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

**TABLE**

<b>Sl. No.</b>	<b>Name of the Scheduled Formulation</b>	<b>Dosage form &amp; Strength</b>	<b>Unit</b>	<b>Ceiling Price (Rs.)</b>
<b>(1)</b>	<b>(2)</b>	<b>(3)</b>	<b>(4)</b>	<b>(5)</b>
1.	Anti-D Immunoglobulin	Injection 150mcg	Each Vial	1509.69

**Note:**

- All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.
- All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the

DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/183/51/2017/F

F. No. 8(51)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India  
Ministry of Chemicals and Fertilizers  
Department of Pharmaceuticals  
National Pharmaceutical Pricing Authority

New Delhi, the 18<sup>th</sup> December, 2017

ORDER

S.O. ....Whereas, the Department of Pharmaceuticals (hereinafter referred as DOP) has amended Schedule I of the Drugs Price Control Order (hereinafter referred as DPCO) 2013 vide S.O. 701(E) dated 10.03.2016 based on revised National List of Essential Medicine (hereinafter referred as NLEM) 2015;

and

02. Whereas on amendment of the list of scheduled formulations, paragraph 17 of the DPCO 2013 requires fixation of the ceiling prices of formulations (i.e. medicines) added in the Schedule I to be fixed as per the provisions of the DPCO, 2013 within a period of sixty days from the date of amendment;

and

03. Whereas the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) initiated the process of the ceiling price fixation in March 2016. In this connection, NPPA vide Office Memorandum (i.e. OM) 19(697)/2016/Div II/NPPA dated 4.4.2016 had uploaded a list of the scheduled formulations for which reference market based data required for price fixation was not available. The said list was subsequently amended and displayed again vide OMs dated 28.4.2016, 13.5.2016, 10.1.2017 and 8.7.2017. Copies of the aforesaid OMs were also sent to Drugs Manufacturers Associations requesting for submission of market based data and whereas NPPA had also suggested the Department of Pharmaceuticals to amend DPCO 2013 so as to facilitate consideration of the State Institutional Procurement Price for such scheduled formulations where market based data are not available to facilitate ceiling price fixation;

and

04. Whereas on the basis of inputs from the manufacturer and official data collection agency viz AIOCD AWACS in respect of certain scheduled formulations where market based prices could be traced, NPPA has fixed the ceiling prices of such scheduled formulations. NPPA has so far fixed the ceiling prices of 821 formulations on the basis of available data. However, even after a number of attempts made to obtain the relevant and reliable market based data, NPPA has not been able to fix the ceiling prices of remaining scheduled formulation for the want of requisite market data;

and

05. Whereas, it is obligatory on the part of the NPPA to revise the ceiling prices of all the drugs notified under the Schedule I of DPCO, 2013 so as to ensure the benefit of fair and reasonable ceiling prices to the consumers of such essential medicines to protect public interest, there is a necessity to adopt alternative methods of price fixation;

and

06. Whereas NPPA also sought information from the various Government Procurement Agencies under Central Government and States and State Medical Services Corporation, as it is necessary to fix ceiling prices of scheduled formulations. Accordingly, in the absence of the relevant market based data in the Pharmatrac report of AIOCD- AWACS, it has been decided in the Authority Meeting held in the NPPA on 19/9/2017 to fix the ceiling prices of remaining scheduled formulations on the basis of procurement prices;

and

07. Now, in exercise of the powers conferred by paragraphs 19 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S.O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, which has been upheld by the Honourable High Court and also Hon'ble Supreme court of India and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S. O. 2060(E) and SO 2061(E) dated 30<sup>th</sup> June, 2017, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

**TABLE**

<b>Sl. No.</b>	<b>Name of the Scheduled Formulation</b>	<b>Dosage form &amp; Strength</b>	<b>Unit</b>	<b>Ceiling Price (Rs.)</b>
<b>(1)</b>	<b>(2)</b>	<b>(3)</b>	<b>(4)</b>	<b>(5)</b>
1.	Phenylephrine	Drops 5%	1 ML	3.38

Note:

- (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.
- (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

- (c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/183/51/2017/F

F. No. 8(51)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director